Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/085,896external-prioritypatent/US20030229099A1/en
Priority claimed from US10/325,896external-prioritypatent/US7342016B2/en
Application filed by Schering Corp, Pharmacopeia Drug DiscoveryfiledCriticalSchering Corp
Publication of ECSP045249ApublicationCriticalpatent/ECSP045249A/en
Se describen compuestos tricíclicos novedosos representados por la fórmula (1.0):y una sal ó solvato de los mismos aceptable para uso farmacéutico. Los compuestos son útiles para inhibir la proteína farnesil transferasa. También se describen composiciones farmacéuticas que comprenden compuestos de fórmula 1.0. También se describen métodos para el tratamiento del cáncer utilizando los compuestos de fórmula 1.0.Novel tricyclic compounds represented by formula (1.0) are described: and a salt or solvate thereof acceptable for pharmaceutical use. The compounds are useful for inhibiting farnesyl transferase protein. Pharmaceutical compositions comprising compounds of formula 1.0 are also described. Methods for the treatment of cancer using the compounds of formula 1.0 are also described.
ECSP0452492002-02-272004-08-25
"NEW INHIBITORS OF FARNESIL PROTEINA TRANSFERASA AS ANTITUMOR AGENTS"
ECSP045249A
(en)
ADAMANTAN DERIVATIVES, PROCEDURES FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION, PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITION, AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF MEDICINES